BRCA Mutation-Positive Ovarian Cancer Market

BRCA Mutation-Positive Ovarian Cancer Market Overview

A patient with high grade serious ovarian cancer who carry germline mutations in BRCA 1/2 genes is known as BRCA mutation-positive ovarian cancer. BRCA gene mutations lead to a majority of ovarian and breast cancer cases globally. Genetic screening for BRCA mutations in patients has helped researchers for improved preventive measures and therapeutic development.

According to CDC data, In U.S. nearly 70,000 new patients suffer from ovarian cancer every year. Most patients are diagnosed at advance stages making it difficult to treat them.

BRCA Mutation-Positive Ovarian Cancer Market: Drivers and Restraints

Increasing incidence of ovarian cancers with BRCA mutations globally is expected to drive the BRCA mutation-positive ovarian cancer market. Advanced and early genetic screening of BRCA mutations in general population will drive the BRCA mutation-positive ovarian cancer market. However, high costs involved in genetic screening and low availability of geneticists may hamper growth of BRCA mutation-positive ovarian cancer market in future.

BRCA Mutation-Positive Ovarian Cancer Market: Overview

The global BRCA mutation-positive ovarian cancer market is estimated to show rapid growth over forecast period owing to increasing cases of ovarian cancer in females. BRCA mutation-positive ovarian cancer market has high potential due to development of latest drugs in near future for treating ovarian cancer.

In addition, oral contraceptives are used as an adjuvant therapies in the BRCA mutation-positive ovarian cancer market. In 2017, FDA approved tablet form of Olaparib by Astrazeneca, which is used for maintenance treatment of ovarian cancer.

BRCA Mutation-Positive Ovarian Cancer Market: Regional Overview

The global BRCA mutation-positive ovarian cancer market is expected to be dominated by North America due to availability of reimbursements. Latin America market is emerging in BRCA mutation-positive ovarian cancer market due to increasing governmental spending on healthcare.

Europe market is expected to be the second most growing region in the global BRCA mutation-positive ovarian cancer market owing to latest research and developmental activities. BRCA mutation-positive ovarian cancer market in East Asia and South Asia is expected to show significant growth due to improving healthcare infrastructure.

Middle East and Africa Market is expected to be least lucrative region in the BRCA mutation-positive ovarian cancer market due to poor healthcare facilities and less disease screening facilities.

BRCA Mutation-Positive Ovarian Cancer Market: Key Players

Examples of some of the market participants in BRCA Mutation-Positive Ovarian Cancer market identified across the value chain includes Astrazeneca plc, Merck & Co., Inc., Glaxosmithkline plc, Clovis Oncology, AbbVie Inc., Bristol Myers Squibb Company, Eli Lilly and Company, Johnson & Johnson, Boehringer Ingelheim International GmbH, F. Hoffmann-La Roche Ltd, and, others.

The research report on BRCA mutation-positive ovarian cancer market presents a comprehensive assessment of the market and contains thoughtful insights, facts, historical data, and, statistically supported and industry-validated market data.

It also contains projections using a suitable set of assumptions and methodologies. The research report on BRCA mutation-positive ovarian cancer market provides analysis and information according to market segments such as geographies, application, and end user.

The report covers exhaust analysis on BRCA Mutation-Positive Ovarian Cancer Market

• Market Segments
• Market Dynamics
• Market Size
• Supply & Demand
• Current Trends/Issues/Challenges
• Competition & Companies involved
• Technology
• Value Chain

Report on BRCA Mutation-Positive Ovarian Cancer Market includes regional analysis

• North America (U.S., Canada)
• Latin America (Brazil, Mexico, Argentina)
• Europe (Germany, Italy, France, U.K, Spain, Russia)
• East Asia (China, Japan, South Korea)
• South Asia (India, ASEAN)
• Oceania (Australia, New Zealand)
• Middle East and Africa (GCC Countries, South Africa, Northern Africa)

The report on BRCA mutation-positive ovarian cancer market is a compilation of first-hand information, qualitative and quantitative assessment by industry analysts, inputs from industry experts and industry participants across the value chain.

The report provides in-depth analysis of parent market trends, macro-economic indicators and governing factors along with market attractiveness as per segments. The report also maps the qualitative impact of various market factors on market segments and geographies.

BRCA Mutation-Positive Ovarian Cancer Market: Segmentation

The global BRCA mutation-positive ovarian cancer market is classified on the basis of indication, treatment type, and end user.

Based on indication, BRCA mutation-positive ovarian cancer market is segmented into the following:

• BRCA 1 Ovarian Cancer
• BRCA 2 Ovarian Cancer

Based on treatment type, BRCA mutation-positive ovarian cancer market is segmented into the following:

• Chemotherapy
• Targeted Therapies
• Anti-Angiogenic Agents
• Poly ADP Ribose Polymerase (PARP) inhibitors

Based on end user, BRCA mutation-positive ovarian cancer market is segmented into the following:

• Hospital Pharmacies
• Drug Stores
• Retail Pharmacies
• Online Pharmacies